The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer-Reference-Cited by-同舟云学术

The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer

Published:2015-03-01 Issue:9 Volume:75 Page:897-906
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Graff Rebecca E.¹²,Pettersson Andreas¹,Lis Rosina T.³⁴,DuPre Natalie¹,Jordahl Kristina M.¹,Nuttall Elizabeth¹,Rider Jennifer R.¹⁵,Fiorentino Michelangelo¹⁴⁶,Sesso Howard D.¹⁷,Kenfield Stacey A.¹⁵⁸,Loda Massimo³⁴,Giovannucci Edward L.¹⁵⁹,Rosner Bernard⁵¹⁰,Nguyen Paul L.¹¹,Sweeney Christopher J.¹²,Mucci Lorelei A.¹⁵,

Affiliation:

1. Department of Epidemiology; Harvard School of Public Health; Boston Massachusetts

2. Department of Epidemiology and Biostatistics; University of California, San Francisco; San Francisco California

3. Department of Pathology; Brigham and Women's Hospital; Boston Massachusetts

4. Center for Molecular Oncologic Pathology; Dana-Farber Cancer Institute; Boston Massachusetts

5. Channing Division of Network Medicine; Brigham and Women's Hospital; Harvard Medical School; Boston Massachusetts

6. Pathology Unit; Addarii Institute; S. Orsola-Malpighi Hospital; Bologna Italy

7. Department of Preventive Medicine; Brigham and Women's Hospital; Harvard Medical School; Boston Massachusetts

8. Department of Urology; University of California, San Francisco; San Francisco California

9. Department of Nutrition; Harvard School of Public Health; Boston Massachusetts

10. Department of Biostatistics; Harvard School of Public Health; Boston Massachusetts

11. Department of Radiation Oncology; Dana-Farber/Brigham and Women's Cancer Center; Harvard Medical School; Boston Massachusetts

12. Lank Center for Genitourinary Oncology; Dana-Farber Cancer Institute; Harvard Medical School; Boston Massachusetts

Funder

Prostate cancer

The National Institutes of Health and the National Cancer Institute

National Cancer Institute

Publisher

Wiley

Subject

Urology,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pros.22973/fullpdf

Reference24 articles.

1. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline;Loblaw;J Clin Oncol,2007

2. EAU guidelines on prostate cancer. part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer;Mottet;Actas Urol Esp,2011

3. Long term experience in the treatment of advanced prostatic cancer with decapeptyl, compared to orchiectomy;De Sy;Acta Urol Belg,1988

4. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy;Moreau;Clin Ther,2006

5. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer;Tomlins;Science,2005

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:ERG Fusion Status in Prostate Cancer Using Whole Slide Images;Molecular Cancer Research;2024-01-29

2. Pre-Clinical Models to Study Human Prostate Cancer;Cancers;2023-08-22

3. Computational design of DNA binding domain-retained fusion proteins and virtual screening against FDA-approved drugs;2023-05-08

4. Portrait of Molecular Signaling and Putative Therapeutic Targets in Prostate Cancer with ETV4 Fusion;Biomedicines;2022-10-20

5. To bind or not to bind: Cistromic reprogramming in prostate cancer;Frontiers in Oncology;2022-09-23